International journal of antimicrobial agents · 2026
Distribution of piperacillin-tazobactam into cerebrospinal, peritoneal, and pleural fluid in children aged 0-18 years.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Jinglei, Yang Wenyu, Lei Alice, Harwood Kiera, Boast Alison, Gonis Gena, Di Carlo Amanda, Chiletti Roberto, Daley Andrew, McWhinney Brett, Ungerer Jacobus, Zhu Xiao, Gwee Amanda
Аннотация
BACKGROUND: Piperacillin-tazobactam is increasingly used to treat serious infections in children; however, data on its penetration into body fluids remain limited. We aimed to evaluate drug penetration into these sites and identify effective dosing regimens.
METHODS: Free piperacillin-tazobactam concentrations were measured in serum, cerebrospinal fluid (CSF), peritoneal, and pleural fluid. A population pharmacokinetic model was developed to determine the penetration (AUC0 - ∞, target site/AUC0 - ∞, serum) into the relevant sites. Simulations evaluated intermittent (q8h, q6h, q4h) and continuous infusions to achieve 50% fT>MIC in serum, peritoneal, and pleural fluid, and 100% fT>MIC in CSF.
RESULTS: 103 children (median age 7.0 y; range 0-17.3) were included. Using the final four-compartment model, the median penetration from serum into CSF, peritoneal, and pleural fluid was 0.02, 1.00, and 0.85 for piperacillin, and 0.07, 1.48, and 1.05 for tazobactam, respectively. Simulations demonstrated: in serum, for a minimum inhibitory concentration (MIC) of 16 mg/L, 100 mg/kg q8h was only sufficient in children <3 months and ≥12 y, while children 2-12 y and 3 months- <2 y required q6h and q4h or continuous infusions, respectively; q8h achieved a ≥90% probability of target attainment for an MIC ≤ 16 mg/L in peritoneal and pleural fluid; for CSF, a ≥90% probability of target attainment was achieved only at an MIC ≤ 0.25 mg/L.
CONCLUSIONS: Piperacillin-tazobactam has high penetration in peritoneal and pleural fluid, achieving therapeutic concentrations with 100 mg/kg q8h dosing in all ages. The low CSF penetration is insufficient for Gram-negative meningitis (MIC > 0.25 mg/L). Children aged 3 months to <2 y require more frequent dosing to reach serum targets.
METHODS: Free piperacillin-tazobactam concentrations were measured in serum, cerebrospinal fluid (CSF), peritoneal, and pleural fluid. A population pharmacokinetic model was developed to determine the penetration (AUC0 - ∞, target site/AUC0 - ∞, serum) into the relevant sites. Simulations evaluated intermittent (q8h, q6h, q4h) and continuous infusions to achieve 50% fT>MIC in serum, peritoneal, and pleural fluid, and 100% fT>MIC in CSF.
RESULTS: 103 children (median age 7.0 y; range 0-17.3) were included. Using the final four-compartment model, the median penetration from serum into CSF, peritoneal, and pleural fluid was 0.02, 1.00, and 0.85 for piperacillin, and 0.07, 1.48, and 1.05 for tazobactam, respectively. Simulations demonstrated: in serum, for a minimum inhibitory concentration (MIC) of 16 mg/L, 100 mg/kg q8h was only sufficient in children <3 months and ≥12 y, while children 2-12 y and 3 months- <2 y required q6h and q4h or continuous infusions, respectively; q8h achieved a ≥90% probability of target attainment for an MIC ≤ 16 mg/L in peritoneal and pleural fluid; for CSF, a ≥90% probability of target attainment was achieved only at an MIC ≤ 0.25 mg/L.
CONCLUSIONS: Piperacillin-tazobactam has high penetration in peritoneal and pleural fluid, achieving therapeutic concentrations with 100 mg/kg q8h dosing in all ages. The low CSF penetration is insufficient for Gram-negative meningitis (MIC > 0.25 mg/L). Children aged 3 months to <2 y require more frequent dosing to reach serum targets.